EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische Studie

Real‐World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette‐Guérin ( BCG ) Therapy in BCG ‐Naïve or ‐Unresponsive Non–Muscle‐Invasive Bladder Cancer

Makito Miyake iD, Nobutaka Nishimura, Rikiya Taoka iD, Jun Miki iD, Ryoichi Saito iD, Wataru Fukuokaya iD, Yoshiyuki Matsui, Kei Daizumoto, Yuto Matsushita iD, Takuji Hayashi iD, Junichi Inokuchi, Yusuke Sugino und 9 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70314 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Makito Miyake und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nara Medical University, Nara, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, BCG Vaccine, Cystectomy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare survival outcomes between Japanese patients receiving radical cystectomy (RC) and intravesical Bacillus Calmette–Guérin (BCG) for high‐risk non–muscle‐invasive bladder cancer (HR‐NMIBC).

Methods

This study was conducted within the Japanese Urological Oncology Group (JUOG) framework using two nationwide, multi‐institutional databases: JUOG‐UC‐2021‐RC, comprising 2674 patients with bladder cancer who underwent RC, and JUOG‐UC‐1901‐BCG, comprising 3226 patients who received intravesical BCG. Patients were classified according to the Japanese Urological Association guideline (version 2023) risk stratification model into three cohorts: BCG‐naïve standard HR‐NMIBC (without aggressive factors), BCG‐naïve highest‐risk NMIBC (an aggressive subgroup), and BCG‐unresponsive NMIBC. Metastasis‐free survival (MFS) and overall survival (OS) were compared between the two interventions. Propensity score matching was applied to create well‐balanced groups (BCG vs RC).

Results

In the adjusted BCG‐naïve standard HR‐NMIBC subcohort, both MFS and OS were longer in the BCG‐treated group than in the RC group ( p = 0.15 and p = 0.027, respectively). However, no significant differences in MFS or OS were observed in the adjusted BCG‐naïve highest‐risk NMIBC subcohort ( p = 0.20 and p = 0.47, respectively). In the adjusted BCG‐unresponsive NMIBC cohort, no differences in MFS or OS were detected ( p = 0.76 and p = 0.35, respectively), although long‐term survival outcomes appeared better in the salvage RC group than in the BCG rechallenge group.

Conclusions

Our findings demonstrated that the RC group had worse outcomes than the BCG group in the BCG‐naïve standard HR‐NMIBC subcohort but not in the highest‐risk or BCG‐unresponsive cohorts. Accumulating evidence is essential to guide physicians in counseling patients with HR‐NMIBC and BCG‐unresponsive NMIBC. Registry and the Registration No. of the Study/Trial The authors have nothing to report.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsBCG VaccineCystectomyHumansMaleFemaleAgedAdministration, IntravesicalMiddle AgedAdjuvants, ImmunologicNeoplasm InvasivenessJapanTreatment OutcomeRetrospective StudiesRisk AssessmentPropensity ScoreAged, 80 and overUrinary BladderNon-Muscle Invasive Bladder Neoplasms

Stichwörter der Autor:innen

Bacillus Calmette–Guérincystectomyprognosisriskurinary bladder neoplasms

Substanzen

BCG VaccineAdjuvants, Immunologic

Autor:innen und Institutionen

  • Department of Urology, Nara Medical University, Nara, Japan.
  • Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan.
  • Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Urology, Hyogo College of Medicine, Hyogo, Japan.
  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.

ORCID-Profile: Makito Miyake, Rikiya Taoka, Jun Miki, Ryoichi Saito, Wataru Fukuokaya, Yuto Matsushita, Takuji Hayashi, Kiyohide Fujimoto

Zitieren

APA

Miyake, M., Nishimura, N., Taoka, R., Miki, J., Saito, R., Fukuokaya, W., Matsui, Y., Daizumoto, K., Matsushita, Y., Hayashi, T., Inokuchi, J., Sugino, Y., Shiga, K., Yamaguchi, N., Yamamoto, S., Yasue, K., Nishiyama, N., Nishiyama, H., Kitamura, H., …, & Japanese Urological Oncology Group (2026). Real‐World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette‐Guérin ( BCG ) Therapy in BCG ‐Naïve or ‐Unresponsive Non–Muscle‐Invasive Bladder Cancer. International Journal of Urology. https://doi.org/10.1111/iju.70314

Vancouver

Miyake M, Nishimura N, Taoka R, Miki J, Saito R, Fukuokaya W, et al. Real‐World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette‐Guérin ( BCG ) Therapy in BCG ‐Naïve or ‐Unresponsive Non–Muscle‐Invasive Bladder Cancer. International Journal of Urology. 2026. doi:10.1111/iju.70314

BibTeX
@article{Miyake2026,
  author = {Miyake, Makito and Nishimura, Nobutaka and Taoka, Rikiya and Miki, Jun and Saito, Ryoichi and Fukuokaya, Wataru and Matsui, Yoshiyuki and Daizumoto, Kei and Matsushita, Yuto and Hayashi, Takuji and Inokuchi, Junichi and Sugino, Yusuke and Shiga, Kenichiro and Yamaguchi, Noriya and Yamamoto, Shingo and Yasue, Keiji and Nishiyama, Naotaka and Nishiyama, Hiroyuki and Kitamura, Hiroshi and Fujimoto, Kiyohide and Japanese Urological Oncology Group, Japanese Urological Oncology Group},
  title = {Real‐World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette‐Guérin ( BCG ) Therapy in BCG ‐Naïve or ‐Unresponsive Non–Muscle‐Invasive Bladder Cancer},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70314}
}
Kostenlos starten →